Sublingual allergen immunotherapy in HIV-positive patients

Area of Science:

• Allergy and Immunology
• Infectious Diseases
• Immunotherapy

Background:

• HIV infection historically contraindicates allergic immunotherapy (AIT).
• Highly active antiretroviral therapy (HAART) has improved immune function and life expectancy in HIV-positive individuals.
• Respiratory allergy incidence in HIV patients on HAART is comparable to the general population.

Purpose of the Study:

• To evaluate the safety and clinical effectiveness of sublingual immunotherapy (SLIT) in grass pollen-allergic HIV-positive patients on HAART.
• To assess the impact of SLIT on allergy symptoms, quality of life, viral load, and TCD4 cell counts.

Main Methods:

• A group of 13 grass pollen-allergic HIV-positive patients on HAART received SLIT (Oralair, Stallergenes©) plus symptomatic therapy.
• A control group of 9 patients received symptomatic therapy alone.
• Clinical efficacy was measured using total combined score (TCS), symptom-medication score, and quality of life (QoL) questionnaires.
• HIV viral load (VL) and peripheral TCD4 lymphocytes were monitored.

Main Results:

• SLIT-treated patients showed significant improvements in TCS (P = 0.0001) and QoL (P = 0.03) compared to controls.
• No significant alterations in TCD4 cell counts or viral load were observed in either group.
• SLIT was well-tolerated by the study participants.

Conclusions:

• Sublingual immunotherapy (SLIT) is a safe and effective treatment option for grass pollen allergy in HIV-positive patients with controlled viral load and immune function on HAART.
• SLIT can improve allergic symptoms and quality of life without compromising HIV disease control.
• These preliminary findings support the use of SLIT in this specific patient population.